Aberdeen Health Technology Assessment (HTA) Group



HSRU, in collaboration with HERU and the section of Population Health within the University of Aberdeen is one of the nine independent academic centres in the UK commissioned to undertake technology assessment reviews (TARs) for NICE and also TARs and short reports for other NHS customers. NICE carry out appraisals of health technologies at the request of the Department of Health and provides guidance to the NHS on the clinical and cost effectiveness of selected new and established technologies. Guidance produced by NICE on health technologies is mandatory in England and Wales and applied selectively in Scotland (via the Scottish Health Technology Group and the Scottish Medicines Consortium) and Northern Ireland. The University of Aberdeen is the only academic centre in Scotland to hold a TAR contract and HSRU has been involved in the contract since 2001. The TAR work involves preparing a critique of the clinical effectiveness and cost effectiveness evidence submitted to NICE by the pharmaceutical companies in support of their cases to have new or existing drugs reimbursed by the NHS as well as broader evidence syntheses that, apart from a systematic review of current clinical effectiveness evidence, may include the development of an economic model to estimate the cost-effectiveness of alternative therapeutic or diagnostic interventions.

In 2014, the TAR contract was successfully renewed for the 2016-2021 period. The previous TAR contract covered the 2011-2016 period.


Miriam Brazzelli; m.brazzelli@abdn.ac.uk



Current Projects

Single Technology Assessments

Dupilumab for treating adults with moderate to severe atopic dermatitis

Teduglutide for treating short bowel syndrome

Multiple Technology Assessments

None at present

Diagnostic Assessment Reviews

None at present

Health Technology Assessments

The clinical and cost-effectiveness of protocols using contrast-enhanced ultrasound and/or colour duplex ultrasound in the long-term surveillance of endovascular abdominal aortic aneurysm repair (EVAR)

The Effectiveness and cost-effectiveness of Surgical Treatments for womEn with stRess urinary incontinence: An evidence synthesis (ESTER)

Interventions for the treatment of painful bladder syndrome (eg Interstitial cystitis)

Completed Projects

Single Technology Assessments

Aflibercept solution for injection for the treatment of wet age-related macular degeneration

Aflibercept DMO: Aflibercept for treating diabetic macular oedema

Aflibercept BRVO: Aflibercept for treating visual impairment due to macular oedema secondary to branch retinal vein occlusion

Brentuximab Vedotin is recommended by NICE for treatment of relapsed or refractory systemic anaplastic large cell lymphoma (sALCL)

Eluxadoline for treating irritable bowel syndrome with diarrhoea 

Enzalutamide for treating metastatic hormone-relapsed prostate cancer not previously treated with chemotherapy

Ibrutinib for treating relapsed or refractory chronic lymphocytic leukaemia

Radium-223 dichloride for treating metastatic hormone relapsed prostate cancer with bone metastases [ID576] Single Technology Appraisal

Pazopanib for the first line treatment of patients with advanced and/or metastatic renal cell carcinoma: A Single Technology Appraisal

Pembrolizumab for treating advanced or recurrent PD-L1 positive non-small-cell lung cancer after progression with platinum-based chemotherapy

Eltrombopag for the treatment of chronic idiopathic (immune) thrombocytopenic purpura (ITP): A Single Technology Appraisal

Romiplostim for the treatment of chronic immune or idiopathic thrombocytopenic purpura (ITP): A Single Technology Appraisal

Dapagliflozin for the treatment of type 2 diabetes

Ranibizumab for the treatment of choroidal neovascularisation associated with pathological myopia

Secukinumab for treating moderate to severe plaque psoriasis

Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia

Ezetimibe for treating primary (heterozygous-familial and non-familial) hypercholesterolaemia

Multiple Technology Assessments

Collagenase clostridium histolyticum for the treatment of Dupuytren’s contracture

Systematic review of the clinical and cost-effectiveness of imatinib at escalated doses of 600 mg/day or 800 mg/day for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours which have progressed on treatment at a dose of 400 mg/day

Systematic review of the clinical and cost-effectiveness, and economic evaluation of denosumab for the treatment of bone metastases from solid tumours

Diagnostic Assessment Reviews

Point-of-care tests (CoaguChek system, INRatio2 PT/INR monitor and ProTime Microcoagulation system) for the self-monitoring of the coagulation status of people receiving long-term vitamin K antagonist therapy compared with standard UK practice

The clinical and cost-effectiveness of Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: systematic review and economic evaluation

Multiple frequency bioimpedance devices (BCM - Body Composition Monitor, BioScan 920-II, BioScan touch i8, InBody S10, and MultiScan 5000) for fluid management in people with chronic kidney disease having dialysis

Health Technology Assessments

Open mesh repairs in adults presenting with a clinically diagnosed unilateral, primary inguinal hernia

Systematic review of the clinical and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer

Systematic review of the clinical and cost-effectiveness of rapid point-of-care tests for the detection of genital Chlamydia infection in women and men

Systematic review of the clinical and cost-effectiveness of 64-slice or higher computed tomography angiography as an alternative to invasive coronary angiography in the investigation of coronary artery disease (CAD)

Systematic review of the clinical effectiveness and cost-effectiveness of oesophageal Doppler monitoring in critically ill and high risk surgical patients

Systematic review of the clinical effectiveness and cost-effectiveness and economic modelling of minimal incision total hip replacement approaches in the management of arthritic disease of the hip

Clinical and cost-effectiveness of cholecystectomy versus observation/conservative management for preventing recurrent symptoms and complications in adults presenting with uncomplicated symptomatic gallstones or cholecystitis

MRS/MRI: Systematic review of the diagnostic accuracy and cost-effectiveness of magnetic resonance spectroscopy and enhanced magnetic resonance imaging techniques in aiding the localisation of prostate abnormalities for biopsy

Alpha-2 agonists for sedation of mechanically ventilated adults in intensive care units: a systematic review

Fast Track Appraisal (FTA)

Aflibercept CNV: Aflibercept for treating myopic choroidal neovascularisation.  Fast track appraisal: cost comparison case